SureTrader SureTrader
Home > Boards > US OTC > Medical - Drugs >

Cellceutix Corporation (CTIX)

CTIX RSS Feed
Add CTIX Price Alert      Hide Sticky   Hide Intro
Moderator: BigKahuna, BooDog, TOB, sox040713, Astavakra, TheHound
Search This Board:
Last Post: 12/3/2016 4:33:53 PM - Followers: 702 - Board type: Free - Posts Today: 27

Cellceutix Corporation (CTIX)
 

 

http://cellceutix.com/
 
Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
Phone: 978-236-8717
Fax:  978-921-6564
Email:  info@cellceutix.com
 
About Cellceutix: 

Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol “CTIX”. Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Cellceutix believes it has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix’s anti-cancer drug Kevetrin concluded a Phase 1 clinical trial at Harvard Cancer Centers’ Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Cellceutix is now preparing its FDA application for a Phase 2 ovarian cancer study. In the laboratory, Kevetrin has shown to induce activation of p53, often referred to as the “Guardian Angel Gene” due to its crucial role in controlling cell mutations. Cellceutix is in a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention of Oral Mucositis in patients with head and neck cancer. Brilacidin-OM, a defensin mimetic compound, has shown in an animal model to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix’s anti-psoriasis drug Prurisol completed a Phase 2 trial. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix’s lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria (Superbugs). Brilacidin is also being evaluated in a Phase 2 Proof-of-Concept trial as a novel treatment for Ulcerative Proctitis. Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available on the Cellceutix web site at www.cellceutix.com. 

Management:  http://cellceutix.com/team/

Ongoing Human Trials:  http://clinicaltrials.gov/ct2/results?term=Cellceutix+Pharmaceuticals&Search=Search
 
Product Pipeline:  http://cellceutix.com/pipeline/

 

Upcoming Milestones:
 


Recent News and Press Releases: 
http://finance.yahoo.com/q/h?s=CTIX+Headlines

Seeking Alpha focus articles on CTIX: http://seekingalpha.com/symbol/CTIX
 
http://cellceutix.com/category/press-release/

A randomized, double-blind study comparing single-dose and short-course brilacidin to daptomycin in the treatment of acute bacterial skin & skin structure infections (ABSSSI)

http://eccmid.meetingexpert.net/ECCMID_546/poster_122533/program.aspx/anchor122533

Synthetic novel host defense protein mimetics for the treatment of Gram-negative bacterial infections

http://eccmid.meetingexpert.net/ECCMID_546/poster_122353/program.aspx

 
SEC Filings (CIK:0001355250):  http://www.sec.gov/cgi-bin/browse-edgar?company=Cellceutix+Corp&match=&CIK=ctix&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany

Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
cs@wcsti.com
http://www.westcoaststocktransfer.com/

 
Share Structure:  See SEC filing link above for current share structure
 

Cellceutix IP - Patent Filings:

EPO
http://worldwide.espacenet.com/searchResults?PA=Cellceutix&DB=EPODOC&locale=en_EP&ST=advanced&compact=false
WIPO
http://www.wipo.int/patentscope/search/en/detail.jsf?docId=WO2010135170&recNum=1&docAn=US2010034838&queryString=FP:(Cellceutix)&maxRec=1
USPTO
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=Cellceutix&FIELD1=AS&co1=AND&TERM2=&FIELD2=&d=PG01 


http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,796,275.PN.&OS=PN/8,796,275&RS=PN/8,796,275

 

Publication number US8338454 B2
Publication type Grant
Application number US 12/780,132
Publication date Dec 25, 2012
Filing date May 14, 2010
Priority date May 20, 2009
Also published as CA2762427A1, CN102438612A, EP2432464A2, US20100298374, US20130245062, WO2010135170A2, WO2010135170A3, Less «6 More »
Publication number 12780132, 780132, US 8338454 B2, US 8338454B2, US-B2-8338454, US8338454 B2, US8338454B2
Inventors Krishna Menon
Original Assignee Cellceutix Corporation
Export Citation BiBTeX, EndNote, RefMan
Patent Citations (6), Non-Patent Citations (41), Referenced by (1), Classifications (42)
 
External Links: USPTO, USPTO Assignment, Espacenet


http://www.google.com/patents/US8338454

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=6&f=G&l=50&co1=AND&d=PG01&s1=Cellceutix.AS.&OS=AN/Cellceutix&RS=AN/Cellceutix

 
Investor Relations:  info@cellceutix.com

Following is a WEEKLY chart:


 

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
 
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
 
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CTIX
Current Price
Volume:
Bid Ask Day's Range
SureTrader
CTIX News: Current Report Filing (8-k) 11/15/2016 06:25:29 AM
CTIX News: Quarterly Report (10-q) 11/09/2016 06:06:41 AM
CTIX News: Amended Annual Report (10-k/a) 10/28/2016 05:02:25 PM
CTIX News: Current Report Filing (8-k) 09/15/2016 08:01:38 AM
CTIX News: Current Report Filing (8-k) 09/13/2016 08:01:27 AM
PostSubject
#164163  Sticky Note For your reading enjoyment...Pat Cox's write-up. keltoi 11/17/16 02:24:42 PM
#163870  Sticky Note Cellceutix Q1 Fiscal 2017 Conference Call BooDog 11/15/16 10:13:00 AM
#163817  Sticky Note Cellceutix Provides Corporate Update and Reports Q1 Fiscal BigKahuna 11/14/16 07:53:35 PM
#162983  Sticky Note CTIX Upcoming and Past Milestones, Clinical Trials, Recent Interviews sox040713 11/01/16 12:36:11 PM
#161171  Sticky Note B-UP Due Diligence sox040713 10/10/16 07:21:01 PM
#117003  Sticky Note Cellceutix released efficacy data for Kevetrin, its cancer TOB 08/09/15 03:05:24 PM
#165095   I would like to see us move from tombrady12nh 12/03/16 03:53:36 PM
#165093   Prurisol metabolism ... where does the MOA reside? JSN2000 12/03/16 02:43:16 PM
#165092   Saturday's Post of the Day. 45 days or Matagordaville 12/03/16 02:38:26 PM
#165091   since we're on the subject,... several years worth TheHound 12/03/16 02:34:28 PM
#165089   Dane, I didn't expect to see Reverse Split sox040713 12/03/16 01:35:13 PM
#165088   What I love about America and investing in TheDane 12/03/16 12:49:00 PM
#165087   Hmmm...but has ONE company done ALL those things? scottsmith 12/03/16 12:24:45 PM
#165086   George Dr. B accelerated the OM trial. runninggirl2016 12/03/16 11:37:54 AM
#165083   Yes, but Dr. Bertolino MD I believe has georgejjl 12/03/16 11:06:17 AM
#165082   Great answer Amatuer17 12/03/16 10:58:03 AM
#165081   Actually a lot of co have done all Amatuer17 12/03/16 10:52:26 AM
#165079   govorchin looks like they decided to run 1 runninggirl2016 12/03/16 10:45:55 AM
#165078   what happened to B UP? govorchin 12/03/16 10:10:57 AM
#165077   George only the P 2B trial started on runninggirl2016 12/03/16 09:58:05 AM
#165076   Bring it on! And the CEO change! Actually, scottsmith 12/03/16 09:36:42 AM
#165075   A reverse 5 for 1 split would get Giovanni 12/03/16 09:29:39 AM
#165074   George I agree on the 4 out of runninggirl2016 12/03/16 09:29:35 AM
#165073   Since Dr. Bertolino MD became President of Cellceutix georgejjl 12/03/16 09:26:18 AM
#165072   JT Prurisol is Golden. No need to be scared. runninggirl2016 12/03/16 09:14:25 AM
#165071   OK guys runninggirl2016 put it all in a JTORENCE 12/03/16 08:39:50 AM
#165070   GO PRURISOL!!! runninggirl2016 12/03/16 08:19:18 AM
#165069   FINRA short sales of CTIX AlanC 12/02/16 10:55:45 PM
#165068   Cancer is such a complex pathology. Of course frrol 12/02/16 10:13:13 PM
#165067   hmmm. Interesting Trying to answer the question To infinity and beyond! 12/02/16 10:02:53 PM
#165066   Post of the month! TheDane 12/02/16 09:31:51 PM
#165064   Couldn't resist..................again! Blue Fin 12/02/16 08:27:13 PM
#165062   I believe that we should see news within georgejjl 12/02/16 08:23:47 PM
#165061   lance armstrong and fellow testicular cancer survivors might To infinity and beyond! 12/02/16 08:23:21 PM
#165059   Based on that argument there is no point loanranger 12/02/16 08:00:19 PM
#165058   I added shares of CTIX to my portfolio today!!! georgejjl 12/02/16 07:44:00 PM
#165057   A partnership is probably the only thing short septmike09 12/02/16 06:29:13 PM
#165056   Just save your breath.' This .04 drop is DaubersUP 12/02/16 06:28:34 PM
#165055   I disagree. The company's survival is tied to sox040713 12/02/16 06:27:18 PM
#165054   Simply not true. Yes, it contributed and may BigKahuna 12/02/16 05:55:36 PM
#165053   I have it, Leo dismissed as CEO and Rdunn88 12/02/16 05:30:58 PM
#165052   What could management release, right now, to get scottsmith 12/02/16 05:25:20 PM
#165051   Sox, the entire company's survival is tied to Rdunn88 12/02/16 05:07:22 PM
#165050   some of us (think) (wish) mgmt screws up govorchin 12/02/16 04:54:40 PM
#165049   sour milk is good for you! :) vip1999 12/02/16 04:54:33 PM
#165048   When you invest in CTIX you need to tombrady12nh 12/02/16 04:37:03 PM
#165047   Well there are two ways to look at septmike09 12/02/16 04:28:19 PM
#165046   Yes, I can see it might also be TheDane 12/02/16 04:10:52 PM
#165045   I asked them that time as well and Amatuer17 12/02/16 04:03:29 PM
#165044   Chalk this week up as a loser for Rdunn88 12/02/16 04:02:26 PM
#165043   I'm thinking it might be more of a BigKahuna 12/02/16 04:01:54 PM
#165042   GO PRURISOL!!! runninggirl2016 12/02/16 04:01:05 PM
#165041   I'm detecting a theme. Unhappy shareholders have options. TheDane 12/02/16 03:58:13 PM
#165040   Probably a very good chance we get some septmike09 12/02/16 03:57:37 PM
#165039   Aspire and the 1%ers are the only people runninggirl2016 12/02/16 03:56:48 PM
#165038   Bid 54,400 @ $ 1.16 Stack them up!!!!!! Let's roll! Matagordaville 12/02/16 03:56:24 PM
PostSubject